Literature DB >> 30151027

Non-arteritic Posterior Ischaemic Optic Neuropathy Treated with Intravenous Prostaglandin E1 and Oral Corticosteroids.

Robert D Steigerwalt1, M Rosaria Cesarone2, Gianni Belcaro2, Mauro De Angelis3, Antonella Pascarella3, Marcella Nebbioso4.   

Abstract

Intravenous prostaglandin E1 and oral corticosteroids were used to treat the ischaemic phase of a non-arteritic posterior ischaemic optic neuropathy with immediate visual improvement. Non-arteritic posterior ischaemic optic neuropathy is a disorder of reduced blood flow to the retrobulbar optic nerve, usually of acute onset. It has been suggested that high-dose steroid therapy given soon after the onset of visual loss can result in significant visual improvement. This treatment, however, is not universally successful. The addition of a potent vasodilator to the corticosteroids could help restore ocular blood flow and improve visual acuity. This paper presents the use of prostaglandin E1 (PGE1), a powerful vasodilator of the microcirculation, to treat non-arteritic posterior ischaemic optic neuropathy. In this case report a 68-year-old white male with hereditary haemochromatosis was seen 8 hours after sudden loss of visual acuity in his left eye (OS) to 4/10. The diagnosis of non-arteritic posterior ischaemic optic neuropathy was made and he was immediately given oral corticosteroids. Intravenous PGE1 was given the next morning, 24 hours after the sudden loss of vision, once ischaemia of the optic nerve was confirmed by colour Doppler imaging. The visual acuity in the OS improved from 4/10 to 11/10 within 1 day. A visual field (VF) post treatment showed a peripheral scotoma without a central scotoma. At 12 months post treatment the vision OS remained 11/10. No complications due to the use of PGE1 were seen. The authors conclude that PGE1 should be considered in addition to steroids in cases of NA-PION to immediately restore blood flow to the optic nerve and improve visual acuity.

Entities:  

Keywords:  hereditary haemochromatosis; non-arteritic posterior ischaemic optic neuropathy; prostaglandin E1 (PGE1)

Year:  2011        PMID: 30151027      PMCID: PMC6104774          DOI: 10.3109/01658107.2011.559564

Source DB:  PubMed          Journal:  Neuroophthalmology        ISSN: 0165-8107


  14 in total

Review 1.  Mechanism and prevention of ischemia-reperfusion injury.

Authors:  T Kurokawa; H Takagi
Journal:  Transplant Proc       Date:  1999-06       Impact factor: 1.066

2.  Nonarteritic anterior ischemic optic neuropathy treated with intravenous prostaglandin E1 and steroids.

Authors:  Robert D Steigerwalt; M Rosaria Cesarone; Gianni Belcaro; Antonella Pascarella; Mauro De Angelis; Sabrina Bacci
Journal:  Int J Angiol       Date:  2008

3.  [Treatment of severe intermittent claudication: ORACLE-PGE1 short term study. A randomised 40-week study. Evaluation of efficacy and costs].

Authors:  M R Cesarone; G Belcaro; A N Nicolaides; M Griffin; G Geroulakos; G Ramaswami; M Cazaubon; A Barsotti; S Vasdekis; D Christopoulos; G Agus; P Bavera; P Mondani; E Ippolito; F Flenda
Journal:  Minerva Cardioangiol       Date:  2002-12       Impact factor: 1.347

4.  PGE(1) treatment of severe intermittent claudication (short-term versus long-term, associated with exercise)--efficacy and costs in a 20-week, randomized trial.

Authors:  G Belcaro; A N Nicolaides; G Agus; M R Cesarone; G Geroulakos; L Pellegrini; M T De Sanctis; L Incandela; A Ricci; P Mondani; R De Angelis; E Ippolito; A Barsotti; S Vasdekis; A Ledda; D Christopoulos; B M Errichi; H Helmis; U Cornelli; G Ramaswami; M Dugall; M Bucci; G Martines; P G Ferrari; M Corsi; D Di Francescantonio
Journal:  Angiology       Date:  2000-08       Impact factor: 3.619

Review 5.  Posterior ischaemic optic neuropathy: clinical features, pathogenesis, and management.

Authors:  S S Hayreh
Journal:  Eye (Lond)       Date:  2004-11       Impact factor: 3.775

6.  Clinical spectrum of posterior ischemic optic neuropathy.

Authors:  S R Sadda; M Nee; N R Miller; V Biousse; N J Newman; A Kouzis
Journal:  Am J Ophthalmol       Date:  2001-11       Impact factor: 5.258

7.  Treatment of severe intermittent claudication with PGE1--a short-term vs a long-term infusion plan--a 20 week, European randomized trial--analysis of efficacy and costs.

Authors:  G Belcaro; G Laurora; A N Nicolaides; G Agus; M R Cesarone; M T DeSanctis; L Incandela; A Ricci; M Cazaubon; E Ippolito; A Barsotti; S Vasdekis; A Ledda; P Iacobitti; D Christopoulos; B M Errichi; H Helmis; U Cornelli; G Ramaswami; M Bucci; P G Ferrari; M Corsi; P Pomante; L Mezzanotte; G Geroulakos
Journal:  Angiology       Date:  1998-11       Impact factor: 3.619

8.  Acute branch retinal arterial embolism successfully treated with intravenous prostaglandin E1--case reports.

Authors:  Robert D Steigerwalt; Nicola Pescosolido; Marcello Corsi; M Rosaria Cesarone; Gianni V Belcaro
Journal:  Angiology       Date:  2003 Jul-Aug       Impact factor: 3.619

Review 9.  Mechanisms of anti-ischemic action of prostaglandin E1 in peripheral arterial occlusive disease.

Authors:  K Schrör; T Hohlfeld
Journal:  Vasa       Date:  2004-08       Impact factor: 1.961

10.  Non-arteritic anterior ischemic optic neuropathy: role of systemic corticosteroid therapy.

Authors:  Sohan Singh Hayreh; M Bridget Zimmerman
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2008-04-11       Impact factor: 3.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.